Health Care · Pharmaceutical Preparations

AARD Aardvark Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 177485742 filings
Russell 2000

AARD at a glance

Aardvark Therapeutics, Inc. (AARD, SEC CIK 1774857) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Aardvark Therapeutics, Inc. (AARD) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $57.6 million. Diluted EPS was -$2.93.
  • As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Aardvark Therapeutics, Inc. (AARD) shares worth $12.1 million in 13F-HR filings.
  • In the last 90 days, AARD insiders reported 0 open-market purchases ($0) and 2 open-market sales ($395K) on Form 4, a net sale of $395K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
−100.0% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$395K
13F holders
16 funds
$12.1M · +1 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved for sale
  • Net loss $19.2M vs $16.3M YoY, operating loss $19.7M vs $17.7M
  • R&D expense $15.7M vs $13.7M, worst-performing line, driven by cardiac safety studies
  • Cash, equivalents and short-term investments $60.3M at September 30, 2026, funding projected through 2027
  • FDA clinical hold lifted in October 2026, ARD-201 development paused, FDA meeting scheduled for first quarter 2027

Risk Factors

  • New regulatory risk triggered by October 2026 FDA clinical-hold lifting: no alignment yet on ARD-101 Phase 3 design, dose, or additional studies
  • Most material update: cardiac safety findings led to HERO and OLE termination after 67 participants, despite FDA attribution of serious event to pitolisant interaction
  • Near-term clinical risk: exploratory HERO and OLE data may not support future development, with HERO terminated before planned 90 participants
  • Financial risk: $60.3 million cash, cash equivalents and short-term investments expected to fund operations through 2027, but new Phase 3 requires additional funding
  • Market risk: PWS’s limited patient pool may delay enrollment, especially after prior clinical pauses and ARD-101 clinical hold

AI summary of the AARD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Business updates included in November 13, 2026 press release

Item EX-99.1: Item EX-99.1

  • FDA lifted ARD-101’s PWS clinical hold, enabling an open-label trial at 200 mg twice daily
  • FDA meeting scheduled for Q1 2027, with PWS clinical activities expected to resume in 2027 subject to alignment
Filed Oct 23, 2026Full analysis →

Item 8.01: Other Events

  • Exploratory efficacy data released from terminated Phase 3 HERO and OLE trials
  • Investor webinar held October 23, 2026 at 8:00 a.m. ET

Item EX-99.1: Item EX-99.1

  • HERO trial stopped early with 67 of 90 planned participants, making all efficacy results exploratory
  • OLE participants switching from placebo to ARD-101 showed average HQ-CT reduction of 6 points by Day 28

Item EX-99.2: Item EX-99.2

  • FDA clinical hold lifted in October 2026, allowing Aardvark to resume ARD-101 development for Prader-Willi syndrome
  • HERO enrollment truncated at 67 participants versus planned 90, making efficacy results exploratory rather than confirmatory
Filed Oct 22, 2026Full analysis →

Item 8.01: Other Events

  • FDA lifted the clinical hold on ARD-101’s Investigational New Drug application
  • Regulatory clearance enables clinical development for hyperphagia in Prader-Willi Syndrome

Item EX-99.1: Item EX-99.1

  • FDA lifted the clinical hold on ARD-101, reopening a path for Prader-Willi Syndrome development
  • Prior hold followed reversible ECG changes, creating a key cardiac-safety overhang for investors

AI summaries of AARD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AARD

Don't miss the next AARD filing

  • Alerts as it files. A push when AARD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AARD, by share count.
  • Ask anything. An AI agent that reads every AARD filing and answers with sources.

AARD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Lee Tien-LiANov 6, 2026-
Sun NelsonDNov 6, 2026-
Lee Tien-LiDNov 6, 2026-
Sun NelsonDNov 6, 2026-
Sun NelsonDNov 6, 2026-
Sun NelsonANov 6, 2026-
Lee Tien-LiANov 6, 2026-
Sun NelsonANov 6, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.4M$0
Operating Income--$22.8M-$62.7M
Net Income--$20.6M-$57.6M
Op. Margin--943.9%-
Net Margin--852.9%-
Balance Sheet
Total Assets-$77.5M$117.2M
Equity-$34.8M-$54.6M$106.6M
ROE-37.7%-54.0%
Per Share
EPS-$-5.15$-2.93
Cash Flow
Operating CF--$18.1M-$54.2M
CapEx-$109K$95K

Source: XBRL data in Aardvark Therapeutics, Inc. (AARD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AARD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AARD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202616$12.1M
Q2 202615$17.0M
Q1 202620$13.5M
Q4 202515$50.6M
Q3 202516$38.5M
Q2 202511$28.1M
Q1 20259$11.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 102 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AARD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
10-QNov 13, 2026Analysis
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
8-KOct 23, 2026Analysis-
8-KOct 22, 2026Analysis-
8-KOct 8, 2026Analysis-
4Oct 8, 2026--
4Sep 11, 2026--
4Aug 21, 2026--
4Aug 21, 2026--
4Aug 21, 2026--
4Aug 21, 2026--
8-KAug 17, 2026Analysis-
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
8-KJun 12, 2026Analysis-
8-KMay 14, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
8-KMar 24, 2026--
10-KMar 23, 2026-
8-KMar 23, 2026--
8-KFeb 27, 2026Analysis-

Related Health Care companies

All Health Care →

AARD SEC filings: frequently asked questions

Are AARD insiders buying or selling?

In the last 90 days, Aardvark Therapeutics, Inc. (AARD) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $394,957 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AARD stock?

As of September 30, 2026, the largest Aardvark Therapeutics, Inc. (AARD) holders among the 13F filers tracked by SignalX were Citadel Advisors LLC ($5.1 million), Vanguard Capital Management LLC ($2.9 million), BlackRock ($1.0 million), Two Sigma Investments ($683,000), AQR Capital Management ($602,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AARD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Aardvark Therapeutics, Inc. (AARD) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $57.6 million. Diluted EPS was -$2.93. The figures come from the XBRL data in the 10-K.

What did AARD report in its latest 8-K?

Aardvark Therapeutics, Inc. (AARD) filed an 8-K on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest AARD SEC filings?

Aardvark Therapeutics, Inc. (AARD) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 10, 2026.

What is AARD's SEC CIK number?

Aardvark Therapeutics, Inc. (AARD)'s SEC Central Index Key (CIK) is 1774857. EDGAR lists every AARD filing under that number.

Ask anything about AARD

The research agent reads AARD's filings, financials, insider trades and 13F holders, then answers with sources.